GIP receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
A total synthesis of progesterone was reported in 1971 by William S. Johnson. The synthesis begins with reacting the phosphonium salt 7 with phenyl lithium to produce the phosphonium ylide 8. The ylide 8 is reacted with an aldehyde to produce the alkene 9. The ketal protecting groups of 9 are hydrolyzed to produce the diketone 10, which in turn is cyclized to form the cyclopentenone 11. The ketone of 11 is reacted with methyl lithium to yield the tertiary alcohol 12, which in turn is treated with acid to produce the tertiary cation 13. The key step of the synthesis is the π-cation cyclization of 13 in which the B-, C-, and D-rings of the steroid are simultaneously formed to produce 14. This step resembles the cationic cyclization reaction used in the biosynthesis of steroids and hence is referred to as biomimetic. In the next step the enol orthoester is hydrolyzed to produce the ketone 15. The cyclopentene A-ring is then opened by oxidizing with ozone to produce 16. Finally, the diketone 17 undergoes an intramolecular aldol condensation by treating with aqueous potassium hydroxide to produce progesterone.
==== United States ==== In 1992, Pfizer filed a patent covering the substance sildenafil and its use to treat cardiovascular diseases. This would be marketed as Revatio. The patent was published in 1993 and expired in 2012. The patent on Revatio (indicated for pulmonary arterial hypertension rather than erectile dysfunction) expired in late 2012. Generic versions of this low-dose form of sildenafil have been available in the US from a number of manufacturers, including Greenstone, Mylan, and Watson, since early 2013. Health care providers may prescribe generic sildenafil for erectile dysfunction. For a time, the generic was not available in the same dosages as branded Viagra, so using dosages typically required for treating ED required patients to take multiple pills. In 1994, Pfizer filed a patent covering the use of sildenafil to treat erectile dysfunction. This would be marketed as Viagra. This patent was published in 2002 and expired in 2019. Teva sued to have the latter patent invalidated, but Pfizer prevailed in an August 2011 federal district court case. An agreement with Pfizer allowed Teva to begin to provide the generic drug in December 2017. In the United States, Pfizer received two patents for sildenafil: one for its indication to treat cardiovascular disease (marketed as Revatio) and another for its indication to treat erectile dysfunction (marketed as Viagra). The substance is the same under both brand names.
== Life and career == He was born in Lambeth, London, the son of a railway agent, and followed his father into the same employer, as a clerk with the London and South Western Railway Company. He became a church organist and choir master, and joined an amateur operatic company, before he started entertaining on his own account at dinners, parties, smoking concerts, charity events and the like in the 1890s. Accompanying himself on the piano, he introduced topical patter and monologues into his act, and began to appear at music halls and concert halls in and around London. He became a professional entertainer around 1905, and performed regularly at St George's Hall under the management of John Nevil Maskelyne and David Devant. He toured Australia and New Zealand with Maskelyne and Devant's company in 1908, and was credited with much of the tour's success. On his return, billed as "Barclay Gammon and a Piano" and describing himself as a "Society Clown", he became increasingly successful with his patter and songs, most of which he wrote himself, and performed for some years at the Palace Theatre of Varieties.
== Civilian use == MREs have also been distributed to civilians during natural disasters. The National Guard has provided MREs to the public during natural disasters, such as Hurricanes Katrina, Ike, Maria and Sandy; and the 2011 Super Outbreak. The large number of civilians exposed to MREs prompted several jokes during the recent Mardi Gras in New Orleans, with revellers donning clothing made of MRE packets with phrases such as "MRE Antoinette" (referring to Marie Antoinette; the wife of King Louis XVI) and "Man Ready to Eat". The use of rations for noncombat environments has been questioned. While the nutritional requirements are suitable for a combat environment where servicemembers will burn many calories and lose much sodium through sweat, it has been provided as emergency food or even as a standard meal. The high-fat (averaging about 52 grams of fat, 5 grams trans fats) and high-salt content (averaging about 2 grams) are less than ideal for sedentary situations. In the aftermath of Hurricane Katrina, a 77-year-old civilian man with prior congestive heart failure ended up with volume overload from the high sodium content of MREs. The HDR and TOTM account for this nutritional need. Civilian taste-testing of MREs is popular. For example, the YouTuber known as Steve1989MREInfo reviews MREs and other rations from the U.S. or other countries (such as the Individual Meal Pack), as well as vintage rations like the K-ration for content on YouTube. He gives comprehensive reviews and information about each ration he has.
Sources: en.wikipedia.org
== Variation == Many genetic variants of the GC gene are known. They produce 6 main haplotypes and 3 main protein variants (Gc1S, Gc1F and Gc2). The genetic variations are associated with differences in circulating 25-hydroxyvitamin D levels. They have been proposed to account for some of the differences in vitamin D status in different ethnic groups, and have been found to correlate with the response to vitamin D supplementation.
=== 2020: US Open final === Zverev began his 2020 season at the inaugural ATP Cup. Germany was in Group F alongside Australia, Greece, and Canada. Against Australia, he lost to Alex de Minaur in three sets. Australia won the tie over Germany 3–0. Against Greece, he was defeated by Stefanos Tsitsipas. Germany won the tie over Greece 2–1. Against Canada, he was beaten by Denis Shapovalov. Canada won the tie over Germany 2–1. Germany ended third in Group F. Seeded seventh at the Australian Open, he first defeated Marco Cecchinato in the first round in straight sets. After the match, he pledged to donate all his prize money from the tournament to relief efforts for the ongoing bushfires if he won the title, a total of A$4.12 million. He then defeated Egor Gerasimov, Fernando Verdasco, and 17th seed Andrey Rublev to reach the quarterfinals without dropping a set. He defeated 15th seed and 2014 champion, Stan Wawrinka, in the quarterfinals in four sets to reach his first major singles semifinal. He fell in his semifinal match to fifth seed, Dominic Thiem, in four sets. During the week of 24 February, Zverev played at the Mexican Open. Seeded second, he was upset in his second-round match by qualifier Tommy Paul. Starting from 12 March through early August, the ATP suspended tournament play due to the COVID-19 pandemic. At the US Open, Zverev was seeded fifth. He defeated Kevin Anderson in four sets, then beat 19-year old Brandon Nakashima in four sets. In the third round, he beat Adrian Mannarino in four sets before beating Alejandro Davidovich Fokina in straight sets.
=== Improving cell survival === Among the approaches aimed at improving cell survival in the presence of mutant huntingtin are correction of transcriptional regulation using histone deacetylase inhibitors, modulating aggregation of huntingtin, improving metabolism and mitochondrial function and restoring function of synapses.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.